ES2764480T8 - Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato - Google Patents

Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato

Info

Publication number: ES2764480T8
Authority: ES; Spain
Prior art keywords: acamprosate; zonisamide; disease; related disorders; treating alzheimer
Prior art date: 2008-04-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES09738172T

Other languages

English (en)

Other versions

ES2764480T3 (es

Inventor

Daniel Cohen

Ilya Chumakov

Serguei Nabirochkin

Oxana Guerassimenko

Nathalie Cholet

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharnext SA

Original Assignee

Pharnext SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-29

Filing date

2009-04-29

Publication date

2020-07-24

2009-04-29 Application filed by Pharnext SA filed Critical Pharnext SA

2020-06-03 Application granted granted Critical

2020-06-03 Publication of ES2764480T3 publication Critical patent/ES2764480T3/es

2020-07-24 Publication of ES2764480T8 publication Critical patent/ES2764480T8/es

Status Active legal-status Critical Current

2029-04-29 Anticipated expiration legal-status Critical

Links

208000024827 Alzheimer disease Diseases 0.000 title 1
AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title 1
229960004047 acamprosate Drugs 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1
UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 title 1
229960002911 zonisamide Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ES09738172T 2008-04-29 2009-04-29 Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato Active ES2764480T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4858208P	2008-04-29	2008-04-29
PCT/EP2009/055176 WO2009133128A1 (en)	2008-04-29	2009-04-29	Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate

Publications (2)

Publication Number	Publication Date
ES2764480T3 ES2764480T3 (es)	2020-06-03
ES2764480T8 true ES2764480T8 (es)	2020-07-24

Family

ID=40848096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES09738172T Active ES2764480T3 (es)	2008-04-29	2009-04-29	Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato

Country Status (15)

Country	Link
US (3)	US20110269764A1 (es)
EP (2)	EP3560496A1 (es)
JP (2)	JP5933258B2 (es)
KR (1)	KR20110071050A (es)
CN (2)	CN102065858B (es)
AU (1)	AU2009242113B2 (es)
BR (1)	BRPI0911874A2 (es)
CA (1)	CA2722295C (es)
EA (1)	EA024147B1 (es)
ES (1)	ES2764480T3 (es)
IL (2)	IL208981B (es)
MX (1)	MX2010011878A (es)
NZ (1)	NZ589304A (es)
WO (1)	WO2009133128A1 (es)
ZA (1)	ZA201008038B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
ES2332687B1 (es) *	2008-03-13	2011-01-10	Proyecto De Biomedicina Cima, S.L.	Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
WO2009133128A1 (en) *	2008-04-29	2009-11-05	Pharnext	Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2135607A1 (en)	2008-06-18	2009-12-23	Pharnext	Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
LT2889033T (lt)	2008-11-19	2018-07-10	Forum Pharmaceuticals Inc.	Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
US9925282B2 (en)	2009-01-29	2018-03-27	The General Hospital Corporation	Cromolyn derivatives and related methods of imaging and treatment
JP5808319B2 (ja) *	2009-05-11	2015-11-10	フォルムファーマシューティカルズ、インコーポレイテッド	アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
US9387206B2 (en)	2009-11-03	2016-07-12	Pharnext	Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) *	2009-11-03	2011-05-18	Pharnext	New therapeutics approaches for treating alzheimer disease
PE20170923A1 (es)	2010-05-17	2017-07-12	Forum Pharmaceuticals Inc	Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
US9320793B2 (en) *	2010-07-14	2016-04-26	Acumen Pharmaceuticals, Inc.	Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
DE102010062810B4 (de) *	2010-09-07	2014-03-13	Immungenetics Ag	2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
US9867837B2 (en)	2011-03-01	2018-01-16	Pharnext	Compositions for treating neurological disorders
JP6430445B2 (ja) *	2011-03-01	2018-11-28	ファーネクストＰｈａｒｎｅｘｔ	バクロフェンおよびアカンプロセートに基づく神経疾患の治療
EP2705842A1 (en) *	2012-09-05	2014-03-12	Pharnext	Therapeutic approaches for treating parkinson's disease
US9248111B2 (en) *	2011-03-01	2016-02-02	Pharnext	Therapeutic approaches for treating parkinson's disease
UA113165C2 (xx)	2011-03-01	2016-12-26		Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
KR101937782B1 (ko) *	2011-03-01	2019-01-11	파넥스트	바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
US10010515B2 (en)	2011-03-01	2018-07-03	Pharnext	Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en)	2011-03-01	2016-01-26	Pharnext	Compositions for treating amyotrophic lateral sclerosis
US9931326B2 (en)	2011-03-29	2018-04-03	Pharnext	Composition comprising torasemide and baclofen for treating neurological disorders
EP2535049A1 (en)	2011-06-17	2012-12-19	Proyecto de Biomedicina Cima, S.L.	Tadalafil for the treatment of dementia
AU2013224959B2 (en) *	2012-03-01	2017-12-07	Pharnext	New compositions for treating amyotrophic lateral sclerosis
SMT201700373T1 (it) *	2012-03-01	2017-09-07	Pharnext	Nuove composizioni per il trattamento della sclerosi laterale amiotrofica
EP3461481A1 (en)	2012-05-08	2019-04-03	Forum Pharmaceuticals Inc.	Methods of maintaining, treating or improving cognitive function
EP2705841A1 (en)	2012-09-05	2014-03-12	Pharnext	Combinations of nootropic agents for treating cognitive dysfunctions
EP3563849A3 (en)	2012-10-25	2020-02-12	The General Hospital Corporation	Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en)	2012-10-25	2018-08-28	The General Hospital Corporation	Combination therapies for the treatment of Alzheimer's disease and related disorders
US10626163B2 (en)	2013-01-25	2020-04-21	Brandeis University	Methods of modulating GABAergic inhibitory synapse formation and function
CN103040800A (zh) *	2013-01-28	2013-04-17	杭州雷索药业有限公司	吉非罗齐在制备抗血管生成类药物中的应用
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
US10525005B2 (en)	2013-05-23	2020-01-07	The General Hospital Corporation	Cromolyn compositions and methods thereof
CN110305095A (zh)	2013-10-22	2019-10-08	综合医院公司	色甘酸衍生物以及成像和治疗的相关方法
MX2016010409A (es)	2014-02-11	2016-11-30	Pharnext	Combinacion de baclofeno, acamprosato y trigliceridos de cadena media para el tratamiento de trastornos neurologicos.
US20180064748A1 (en) *	2015-03-27	2018-03-08	Yeda Research And Development Co. Ltd.	Methods of treating motor neuron diseases
DK3364993T3 (da)	2015-10-22	2023-01-09	Cavion Inc	Fremgangsmåder til behandling af angelman syndrom
AU2017306558B2 (en)	2016-08-03	2024-09-19	University Of South Florida	Reelin compositions for treatment of neurological disorders
JP2019524865A (ja)	2016-08-31	2019-09-05	ザジェネラルホスピタルコーポレイション	神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
CN111050761A (zh)	2017-04-24	2020-04-21	法奈克斯公司	阿尔茨海默病的基于idalopirdine的组合治疗
CN110770221B (zh) *	2017-04-26	2023-09-08	卡维昂公司	用于改善记忆和认知以及用于治疗记忆和认知障碍的方法
AU2018271895A1 (en) *	2017-05-26	2020-01-16	Chase Therapeutics Corporation	Pharmaceutical combinations of zonisamide and praxipexole, and related methods, for treating synucleinopathies
US10393760B2 (en)	2017-07-05	2019-08-27	Edward J. Goetzl	Specialized excitatory synaptic protein biomarkers of plasma neuronal exosomes for prediction and staging of Alzheimer's disease
JP7202376B2 (ja)	2017-07-20	2023-01-11	エーゼットセラピーズ，インコーポレイテッド	クロモリンナトリウムおよびイブプロフェンの粉末製剤
WO2019038584A1 (en)	2017-08-19	2019-02-28	Ftf Pharma Private Limited	An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
US11439608B2 (en)	2017-09-25	2022-09-13	Qun Lu	Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
AU2019299347A1 (en)	2018-07-02	2021-01-21	Aztherapies, Inc.	Powdered formulations of cromolyn sodium and alpha-lactose
TWI879741B (zh)	2018-10-03	2025-04-11	美商卡凡恩公司	以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
MX2021006869A (es)	2018-12-10	2021-07-02	Massachusetts Gen Hospital	Esteres de cromolin y usos de los mismos.
CN109402124A (zh) *	2018-12-11	2019-03-01	宁夏医科大学总医院	一种环状RNA hsa-circ-0006969及其特异性扩增引物和应用
WO2021207060A1 (en)	2020-04-06	2021-10-14	The General Hospital Corporation	Methods of treatment of coronavirus-induced inflammation conditions
WO2021230131A1 (ja) *	2020-05-11	2021-11-18	株式会社島津製作所	軽度認知障害治療剤
WO2022146914A1 (en)	2020-12-28	2022-07-07	The General Hospital Corporation	Cromolyn derivatives and uses thereof
AU2022338032A1 (en)	2021-08-31	2024-03-07	Cerespir Incorporated	Co-crystals

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6727278B1 (en) *	1986-08-27	2004-04-27	Dms Pharmaceutical Inc.	Pharmaceutically active agents that impede amyloid formation in vivo
JP2654688B2 (ja) *	1989-05-17	1997-09-17	東燃株式会社	オレフィン重合用触媒成分
IL117149A0 (en) *	1995-02-23	1996-06-18	Schering Corp	Muscarinic antagonists
EP1021204B1 (en) *	1997-09-26	2005-12-28	Noven Pharmaceuticals, Inc.	Bioadhesive compositions and methods for topical administration of active agents
DE69830512T2 (de) *	1997-12-26	2006-03-23	Dainippon Pharmaceutical Co., Ltd.	Medikament für neurodegenerative Erkrankungen
US20070004670A1 (en) *	1998-07-31	2007-01-04	Richard Wurtman	Compositions containing citicoline, and methods of use thereof
IL142807A0 (en) *	1998-11-02	2002-03-10	Alza Corp	Controlled delivery of active agents
CA2377301C (en) *	1999-06-14	2009-05-12	Cosmo S.P.A.	Controlled release and taste masking oral pharmaceutical compositions
KR20070104953A (ko) *	2000-03-17	2007-10-29	아지노모토 가부시키가이샤	신경 장애용 약제
JP2003113120A (ja) *	2001-08-03	2003-04-18	Takeda Chem Ind Ltd	徐放性医薬
WO2003051313A2 (en) *	2001-12-18	2003-06-26	Brassica Foundation For Chemoprotection Research, Inc.	Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
US20040102525A1 (en) *	2002-05-22	2004-05-27	Kozachuk Walter E.	Compositions and methods of treating neurological disease and providing neuroprotection
AU2003251829B2 (en) *	2002-07-09	2009-12-10	Radical Therapeutix	Method to inhibit ischemia and reperfusion injury
US20080050315A1 (en) *	2004-03-24	2008-02-28	Stefan Golz	Diagnostics and Therapeutics for Diseases Associated with Protein Kinase, Cgmp-Dependent, Type I (Prkg1)
JP2006143708A (ja) *	2004-10-19	2006-06-08	Ono Pharmaceut Co Ltd	神経変性疾患治療用医薬
DE602006014607D1 (de) *	2005-01-21	2010-07-15	Teva Pharma	Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung
US20090298864A1 (en) *	2005-04-11	2009-12-03	The Trustees Of Columbia University In The City Of New York	Methods for Treating Mild Cognitive Impairment
US20080188510A1 (en) *	2005-05-23	2008-08-07	Eisai R & D Management Co., Ltd.	Novel methods using zonisamide
CN101291663A (zh) *	2005-09-16	2008-10-22	赛诺科学股份公司	预防和治疗睡眠呼吸障碍的方法和工具
PT1954241E (pt) *	2005-11-28	2012-06-01	Orexigen Therapeutics Inc	Formulação de zonisamida de libertação sustentada
WO2008010768A1 (en) *	2006-07-17	2008-01-24	Cereuscience Ab	Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method
WO2008141074A1 (en) *	2007-05-10	2008-11-20	Salk Institute For Biological Studies	Identification of compounds that protect against amyloid diseases
WO2009133128A1 (en) *	2008-04-29	2009-11-05	Pharnext	Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
PL2282778T3 (pl) *	2008-04-29	2017-08-31	Pharnext	Nowe podejścia terapeutyczne do leczenia choroby alzheimera i powiązanych zaburzeń poprzez modulację angiogenezy
DK2282779T3 (da) *	2008-04-29	2013-05-27	Pharnext	Nye terapeutiske fremgangsmåder til behandling af alzheimer sygdom og beslægtede lidelser gennem en modulation af cellestress-respons
EP2322163A1 (en) *	2009-11-03	2011-05-18	Pharnext	New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) *	2009-11-03	2016-07-12	Pharnext	Therapeutic approaches for treating Alzheimer's disease

2009
- 2009-04-29 WO PCT/EP2009/055176 patent/WO2009133128A1/en not_active Ceased
- 2009-04-29 ES ES09738172T patent/ES2764480T3/es active Active
- 2009-04-29 AU AU2009242113A patent/AU2009242113B2/en not_active Ceased
- 2009-04-29 KR KR1020107026052A patent/KR20110071050A/ko not_active Ceased
- 2009-04-29 EP EP19174818.5A patent/EP3560496A1/en not_active Withdrawn
- 2009-04-29 EA EA201071243A patent/EA024147B1/ru not_active IP Right Cessation
- 2009-04-29 JP JP2011506698A patent/JP5933258B2/ja not_active Expired - Fee Related
- 2009-04-29 MX MX2010011878A patent/MX2010011878A/es active IP Right Grant
- 2009-04-29 CA CA2722295A patent/CA2722295C/en not_active Expired - Fee Related
- 2009-04-29 NZ NZ589304A patent/NZ589304A/en not_active IP Right Cessation
- 2009-04-29 EP EP09738172.7A patent/EP2285374B1/en active Active
- 2009-04-29 CN CN200980122702.4A patent/CN102065858B/zh not_active Expired - Fee Related
- 2009-04-29 CN CN201410270079.XA patent/CN104127434B/zh not_active Expired - Fee Related
- 2009-04-29 BR BRPI0911874-8A patent/BRPI0911874A2/pt not_active Application Discontinuation
2010
- 2010-10-28 IL IL208981A patent/IL208981B/en active IP Right Grant
- 2010-10-29 US US12/915,722 patent/US20110269764A1/en not_active Abandoned
- 2010-11-10 ZA ZA2010/08038A patent/ZA201008038B/en unknown
2014
- 2014-06-18 JP JP2014125058A patent/JP2014205697A/ja active Pending
2015
- 2015-11-30 US US14/954,388 patent/US10350195B2/en not_active Expired - Fee Related
2019
- 2019-02-07 IL IL264736A patent/IL264736B/en active IP Right Grant
- 2019-06-06 US US16/433,097 patent/US10874644B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2722295C (en)	2019-01-15
US10350195B2 (en)	2019-07-16
IL208981B (en)	2019-02-28
US20110269764A1 (en)	2011-11-03
US10874644B2 (en)	2020-12-29
EP3560496A1 (en)	2019-10-30
JP2011518860A (ja)	2011-06-30
JP5933258B2 (ja)	2016-06-08
NZ589304A (en)	2012-03-30
MX2010011878A (es)	2011-04-11
EP2285374B1 (en)	2019-09-18
CN104127434B (zh)	2017-10-13
US20190298698A1 (en)	2019-10-03
BRPI0911874A2 (pt)	2018-05-22
AU2009242113B2 (en)	2014-09-11
CN102065858A (zh)	2011-05-18
CN102065858B (zh)	2014-07-02
IL208981A0 (en)	2011-01-31
EP2285374A1 (en)	2011-02-23
JP2014205697A (ja)	2014-10-30
US20160136136A1 (en)	2016-05-19
IL264736B (en)	2020-05-31
CA2722295A1 (en)	2009-11-05
AU2009242113A1 (en)	2009-11-05
KR20110071050A (ko)	2011-06-28
EA201071243A1 (ru)	2011-06-30
CN104127434A (zh)	2014-11-05
EA024147B1 (ru)	2016-08-31
ZA201008038B (en)	2011-08-31
WO2009133128A1 (en)	2009-11-05
ES2764480T3 (es)	2020-06-03

Publication	Publication Date	Title
ES2764480T8 (es)	2020-07-24	Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato
BRPI0818799A2 (pt)	2015-04-22	Composições para o tratamento da doença de parkinson
IL213259A0 (en)	2011-07-31	Composition for the use to treat alzheimer's disease
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
PT1881823E (pt)	2015-03-02	Composições e métodos para o tratamento de transtornos oculares
PT2894165T (pt)	2023-03-17	Métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0914385A2 (pt)	2015-10-20	"composição antiperspirante ou desodorante e processo para a fabricação de uma composição antiperspirante ou desodorante"
DK2303330T4 (da)	2021-09-13	Farmaceutiske sammensætninger til behandling af parkinsons sygdom
IL219412A (en)	2017-05-29	Preparations containing Busimanden for use in the treatment of Alzheimer's or Alzheimer's disease
EP2382176A4 (en)	2015-09-09	USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PL3354276T3 (pl)	2020-09-21	Kompozycje do leczenia zapalenia przewodu pokarmowego
PT2367561E (pt)	2015-10-23	Composições e métodos para o tratamento da doença celíaca
EP2151435A4 (en)	2011-09-14	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BRPI0808950B8 (pt)	2016-11-16	"composições de cuidados pessoais"
PT3415535T (pt)	2021-02-02	Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
BRPI0813553A2 (pt)	2017-05-09	composições farmacêuticas e métodos para tratamento de distúrbios do olho seco
BRPI0911757A2 (pt)	2013-09-17	composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0918670A2 (pt)	2015-12-01	composições e métodos para o tratamento de disordens mediados por ige
DK2276485T3 (da)	2014-10-13	Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
PL2504005T3 (pl)	2014-03-31	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
BRPI1007929A2 (pt)	2015-09-01	"métodos e composições para o tratamento de neovascularização".
BRPI1007603A2 (pt)	2016-02-16	"composição de tratamento do cabelo"
BRPI1013245A2 (pt)	2016-04-05	"composto para o tratamento de distúrbios metabólicos"
BRPI0810947A2 (pt)	2014-10-14	"composição de condicionamento de cabelos"
BRPI0917440A2 (pt)	2015-12-01	composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho